Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Koki Kamada"'
Autor:
Toshiyuki Sumi, Motoki Sekikawa, Yuta Koshino, Daiki Nagayama, Yuta Nagahisa, Keigo Matsuura, Naoki Shijubou, Koki Kamada, Keito Suzuki, Takumi Ikeda, Haruhiko Michimata, Hiroki Watanabe, Yuichi Yamada, Koichi Osuda, Yusuke Tanaka, Hirofumi Chiba
Publikováno v:
Thoracic Cancer, Vol 15, Iss 20, Pp 1572-1581 (2024)
Abstract Background The efficacy of anti‐CTLA‐4 antibody (ipilimumab) plus anti‐programmed cell death 1 antibody (nivolumab) in treating advanced non‐small cell lung cancer (NSCLC) is impeded by an elevated risk of severe immune‐related adv
Externí odkaz:
https://doaj.org/article/ce7d0e0952334636b66f0569062931cd
Autor:
Naoki Shijubou, Toshiyuki Sumi, Koki Kamada, Takeyuki Sawai, Yuichi Yamada, Hisashi Nakata, Yuji Mori, Hirofumi Chiba
Publikováno v:
Thoracic Cancer, Vol 12, Iss 6, Pp 989-992 (2021)
Abstract Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are the standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR mutations. Uncommon mutations, excluding exon 19 deletions and exon 21 L858R,
Externí odkaz:
https://doaj.org/article/be3afe4587274e7a8e58199d4acad178
Autor:
Toshiyuki Sumi, Hirofumi Uehara, Toshiaki Masaoka, Makoto Tada, Yoshiko Keira, Koki Kamada, Naoki Shijubou, Yuichi Yamada, Hisashi Nakata, Yuji Mori, Hirofumi Chiba
Publikováno v:
Thoracic Cancer, Vol 11, Iss 11, Pp 3396-3400 (2020)
A clinical trial of immune checkpoint inhibitors for advanced non‐small cell lung cancer reported an overall survival plateau with a long tail to the survival curve, suggesting that immune checkpoint inhibitors prolong survival. However, little evi
Externí odkaz:
https://doaj.org/article/35de8e9798db4234be915445b5724461
Autor:
Toshiyuki Sumi, Koki Kamada, Naoki Shijubou, Yuichi Yamada, Hisashi Nakata, Yuji Mori, Hirofumi Chiba
Publikováno v:
Respirology Case Reports, Vol 9, Iss 6, Pp n/a-n/a (2021)
Abstract Osimertinib is a potent and irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively acts on both EGFR‐sensitive and EGFR T790M‐resistant mutations. Patients with pre‐treatment EGFR T790M mu
Externí odkaz:
https://doaj.org/article/0cedb960beee460a9f83e1aa6f61dd01
Publikováno v:
Respirology Case Reports, Vol 9, Iss 4, Pp n/a-n/a (2021)
Key message Clinicians should be aware that interstitial shadows with extreme hypertension should be considered as indicators for diffuse alveolar haemorrhage due to pheochromocytoma crisis.
Externí odkaz:
https://doaj.org/article/06cd74ceae51474ab4169601aabb070c
Autor:
Toshiyuki Sumi, Hirofumi Uehara, Makoto Tada, Yoshiko Keira, Koki Kamada, Naoki Shijubou, Yuichi Yamada, Hisashi Nakata, Yuji Mori, Hirofumi Chiba
Publikováno v:
Respirology Case Reports, Vol 9, Iss 3, Pp n/a-n/a (2021)
Abstract Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc). Nintedanib, an antifibrotic drug, has recently been approved for treating SSc‐ILD. Although there have been no reports suggesting the development of pneu
Externí odkaz:
https://doaj.org/article/0897b0f4f2724df3a0ed4c001caa18d6
Autor:
Toshiyuki, Sumi, Motoki, Sekikawa, Yuta, Nagahisa, Keigo, Matsuura, Naoki, Shijubou, Koki, Kamada, Hiroki, Watanabe, Yuichi, Yamada, Yusuke, Tanaka, Hirofumi, Chiba
Publikováno v:
Investigational New Drugs. 40:1315-1321
Compared to chemotherapy alone, monoclonal antibodies like ipilimumab and nivolumab, with or without chemotherapy, improve the prognosis of patients with non-small cell lung cancer (NSCLC), albeit with a higher incidence of immune-related adverse eve
Autor:
Toshiyuki, Sumi, Yuta, Koshshino, Motoki, Sekikawa, Yuta, Nagahisa, Keigo, Matsuura, Naoki, Shijubou, Koki, Kamada, Hiroki, Watanabe, Haruhiko, Michimata, Daiki, Nagayama, Yusuke, Tanaka, Yuichi, Yamada, Hirofumi, Chiba
Publikováno v:
Investigational New Drugs. 40:1298-1305
Pembrolizumab treatment is associated with a favorable prognosis in patients with non-small-cell lung cancer (NSCLC). Here, we investigated the associations among pre-treatment clinical factors, baseline overall tumor burden, and development of sever
Autor:
Koki Kamada, Naoki Shijubou, Toshiyuki Sumi, Yuichi Yamada, Hisashi Nakata, Yuji Mori, Hirofumi Chiba
Publikováno v:
Haigan. 62:221-226
Autor:
Hisashi Nakata, Hirofumi Chiba, Toshiyuki Sumi, Naoki Shijubou, Yuichi Yamada, Koki Kamada, Yuji Mori, Takeyuki Sawai
Publikováno v:
Respiratory Investigation. 59:766-771
1 Background Although the efficacy of lung cancer treatment has improved, it is dependent on a reliable diagnosis via bronchoscopy. Transbronchial biopsy using ultrathin bronchoscopy can help detect small peripheral pulmonary lesions (PPLs), with a h